ReviewCNS neuroscience & therapeutics2023
Contemplating IL-6, a double-edged sword cytokine: Which side to use for stroke pathology?
Review in CNS neuroscience & therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Association Between Peripheral IL-6 Levels in the Acute Stage of Stroke and Poststroke Depression: A Systematic Review and Meta-Analysis.Brain and behavior · 2026Pooled it
- Inflammatory biomarkers in cerebral venous thrombosis versus ischemic stroke: a network meta-analysis.Frontiers in neurology · 2025Pooled it
- Differential prognostic value of circulating biomarkers across small ischemic stroke subtypes.Scientific reports · 2026Article
- Evaluating tocilizumab in ischemic stroke: Findings from the SPAN multicenter trial.Neuropharmacology · 2026Article
- The Effect of Intravenous Thrombolysis and Mechanical Thrombectomy on Change in the Concentrations of Interleukin-18 and Degradation Products of the Endothelial Glycocalyx in Patients with Acute Ischemic Stroke.Life (Basel, Switzerland) · 2026Article
- Microglia-neuron communication in ischemic stroke: from homeostatic signaling to pathological remodeling and therapeutic targeting.Frontiers in molecular biosciences · 2026Review
- Immunological and Inflammatory Biomarkers in the Prognosis, Prevention, and Treatment of Ischemic Stroke: A Review of a Decade of Advancement.International journal of molecular sciences · 2025Review
- Bioinformatics analysis of comorbid mechanisms between ischemic stroke and end stage renal disease.Scientific reports · 2025Article
- Mechanism of disturbed endothelial cell function on angiogenesis following ischemic brain stroke (Review).Experimental and therapeutic medicine · 2025Review
- The Role of IL-6 in Ischemic Stroke.Biomolecules · 2025Review
- Effect and mechanism of Dichloroacetate in the treatment of stroke and the resolution strategy for side effect.European journal of medical research · 2025Review
- The role of inflammation in Ischemic stroke: from biomarker to treatment.Frontiers in immunology · 2025Review
- Effect ofBiomolecules & biomedicine · 2024Article
- Cytokine Storm in COVID-19: Exploring IL-6 Signaling and Cytokine-Microbiome Interactions as Emerging Therapeutic Approaches.International journal of molecular sciences · 2024Review
- Ethanolic extract ofVeterinary world · 2024Article
- Review
- Brain on Fire: How Brain Infection and Neuroinflammation Drive Worldwide Epilepsy Burden.Epilepsy currents · 2024Review
- Review
- Systemic immune inflammation index and risk of stroke: a cross-sectional study of the National Health and Nutrition Examination Survey 2005-2018.Frontiers in neurology · 2024Article
- Progress in stratified stroke characterization-associated with better diagnosis, accurate prognosis and improved treatment strategies.Brain pathology (Zurich, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Interleukin (IL)-6 is a unique cytokine due to its dual signaling, with one pathway being pro-inflammatory (trans) and the other homeostatic (classical). Both of these pathways have been implicated in neuroinflammation following stroke, with initial inflammatory mechanisms being protective and later anti-inflammatory signaling promoting ischemic tissue recovery. IL-6 plays a major role in stroke pathology. However, given these distinctive IL-6 signaling consequences, IL-6 is a difficult cytokine to target for stroke therapies. Recent research suggests that the ratio between the pro-inflammatory binary IL6:sIL6R complex and the inactive ternary IL6:sIL6R:sgp130 complex may be a novel way to measure IL-6 signaling at different time points following ischemic injury. This ratio may approximate functional consequences on individualized stroke therapies, allowing clinicians to determine whether IL-6 agonists or antagonists should be used at specific time points.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.